PTU-071 Risk stratification of symptomatic patients using faecal biomarkers and urinary volatile organic compounds. (8th June 2018)

• Record Type: Journal Article
• Authors: Widlak, Monika; Neal, Matthew; Daulton, Emma; Thomas, Claire; Tomkins, Claudia; Singh, Baljit; Harmston, Chris; Wicaksono, Alfian; Evans, Charles; Smith, Steve; Savage, Richard; Covington, James; Arasaradnam, Ramesh
• Is Part Of: Gut. Volume 67(2018)Supplement 1
• Page Start: A206
• Page End: A206
• Publication Date: 2018-06-08
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-BSGAbstracts.412
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: There remains an urgent need for non-invasive, low cost methods for diagnosis of colorectal cancer (CRC). We undertook a diagnostic accuracy study using faecal haemoglobin (F-Hb), faecal calprotectin (FCP) and urinary volatile organic compounds (VOCs) in patients presenting with lower gastrointestinal symptoms referred via Two Week Wait colorectal pathway. Methods: Of 1850 patients approached, 1016 were recruited prospectively. Of these, 562 with complete colonic investigations returned matched urine and stool samples and were included in the final statistical analysis. Results: The sensitivity and specificity for CRC using F-Hb were 0.80 (95% confidence interval (CI): 0.66–0.93) and 0.93 (CI: 0.91–0.95) respectively. The negative predictive value (NPV) was 0.99 (CI: 0.98–1.0). Using urinary VOCs the sensitivity and specificity were 0.63 (CI: 0.46–0.79) and 0.63 (CI: 0.59–0.67) respectively and the NPV was 0.96 (CI: 0.94–0.98). For those with F-Hb negative CRC (false negatives), adding urinary VOCs revealed the sensitivity of 0.97 (CI: 0.90–1.0) and specificity of 0.72 (CI: 0.68–0.76) with the NPV of 1.0 (CI: 0.99–1.0). Conclusions: Urinary VOCs applied to a F-Hb negative group excludes CRC with the NPV of 1.0. Thus, the addition of urinary VOCs shows promise as a second stage test in investigating symptomatic population.